Latest news

Thumbnail image for Xospata bags European Commission approval

Xospata bags European Commission approval

The decision was based on the Phase III ADMIRAL trial, in which one-year survival rates shot to 37% for patients who received Xospata, compared to 17% for patients who received salvage chemotherapy.

25th October 2019

Previous  --   5 6 7 8 9 10 11 12 13 14   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download